Dingdang Health Technology Group Ltd. (HKEX: 09886) reported a fresh share repurchase on 14 July 2026, acquiring 105,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 0.92 and HKD 0.94, for a volume-weighted average of HKD 0.9343. The transaction cost totalled HKD 0.10 million, and the shares have been transferred to the company’s treasury stock.

Following the latest buyback, Dingdang Health’s outstanding share count (excluding treasury shares) fell to 1,254.07 million, while treasury shares rose to 0.58 million. The company’s total issued share capital remains unchanged at 1,254.65 million shares.

Under the repurchase mandate granted on 23 June 2026, the company has so far repurchased 3.44 million shares—equivalent to 0.28 % of the issued share base on the mandate date. A 30-day moratorium on new share issues or treasury share sales is in force until 13 August 2026.

In addition, 14.34 million shares bought back between 19 May and 8 July 2026 are still pending formal cancellation, representing roughly 1.14 % of the current issued shares. Repurchase prices for these shares ranged from HKD 0.83 to HKD 0.97.

The board confirms that all repurchases were conducted in accordance with Hong Kong Stock Exchange listing rules and relevant regulatory requirements.